<DOC>
	<DOCNO>NCT02514603</DOCNO>
	<brief_summary>The primary purpose study assess tolerability prexasertib Japanese participant advance solid cancer .</brief_summary>
	<brief_title>A Study Prexasertib ( LY2606368 ) Japanese Participants With Advanced Cancers</brief_title>
	<detailed_description />
	<criteria>Participant must appropriate candidate experimental therapy , determine investigator , available standard therapy fail Participant must diagnosis cancer advanced metastatic Participant must discontinue previous treatment cancer recover acute effect therapy If participant reproductive potential , must agree use medically approve contraceptive precaution study three month follow last dose study drug If participant female childbearing potential , must negative serum urine pregnancy test within 7 day first dose study drug must breast feeding Participant must symptomatic central nervous system malignancy metastasis Participant must current hematologic malignancy Participant must active symptomatic fungal , bacterial viral infection , include human immunodeficiency virus ( HIV ) Hepatitis A , B , C Participant must serious cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasm metastasis</keyword>
	<keyword>Checkpoint Kinase 1</keyword>
	<keyword>CHK1</keyword>
	<keyword>CHK1 inhibitor</keyword>
</DOC>